Wire · opportunities
Capricor's Duchenne drug gets three-month FDA extension after new data submission
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
The FDA extended Capricor Therapeutics' review period by three months for its cell therapy deramiocel targeting Duchenne muscular dystrophy after the company submitted new 24-month data focused on upper limb function. This follows earlier setbacks including a previous FDA rejection and advisory panel concerns.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 14 Aug 2026 and 25 Aug 2026.
◆ ◆ The Wire takeaway
You must prepare to support regulatory discussions with strong clinical evidence focused on muscle function improvements. This FDA extension shows there is still a chance to reshape drug approval with targeted data, signalling an open window but heightened scrutiny for late-stage biotech developers.
◆ Coverage
7 sources · first reported 14 Aug 2026 · latest 25 Aug 2026
◆ Topics